Search research articles
Contact Us
Filters
Showing results (501-510 of 644) with videos related to
Page
of 65
Sort By:
Cancer
|
November 7, 2003
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
Michele Follen, Frank L Meyskens, Ronald D Alvarez, et al.
Neuron
|
December 24, 2014
Delayed coupling to feedback inhibition during a critical period for the integration of adult-born granule cells
Silvio G Temprana, Lucas A Mongiat, Sung M Yang, et al.
Gynecologic Oncology
|
April 10, 2012
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy
Angela J Ziebarth, Haller Smith, Mary E Killian, et al.
Human Gene Therapy
|
May 18, 2004
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy
Martina Breidenbach, Daniel T Rein, Minghui Wang, et al.
Oncotarget
|
September 12, 2014
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
Zachary C Dobbin, Ashwini A Katre, Adam D Steg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity
Parameshwar J Mahasreshti, Manjula Kataram, Ming H Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 18, 2000
Adenoviral-mediated suicide gene therapy for ovarian cancer
R D Alvarez, J Gomez-Navarro, M Wang, et al.
Gynecologic Oncology
|
June 28, 2001
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
S D Barker, E Casado, J Gomez-Navarro, et al.
Gynecologic Oncology
|
March 4, 2008
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival
David S Alberts, Christian Marth, Ronald D Alvarez, et al.
Gynecologic Oncology Reports
|
January 22, 2026
Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers
Nikita Bastin, Halle Petrie, Marc Robinson, et al.
Page
of 65
Search research articles
Search
Showing results (501-510 of 644) with videos related to
Sort By:
Page
of 65
Cancer
|
November 7, 2003
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
Michele Follen, Frank L Meyskens, Ronald D Alvarez, et al.
Neuron
|
December 24, 2014
Delayed coupling to feedback inhibition during a critical period for the integration of adult-born granule cells
Silvio G Temprana, Lucas A Mongiat, Sung M Yang, et al.
Gynecologic Oncology
|
April 10, 2012
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy
Angela J Ziebarth, Haller Smith, Mary E Killian, et al.
Human Gene Therapy
|
May 18, 2004
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy
Martina Breidenbach, Daniel T Rein, Minghui Wang, et al.
Oncotarget
|
September 12, 2014
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
Zachary C Dobbin, Ashwini A Katre, Adam D Steg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity
Parameshwar J Mahasreshti, Manjula Kataram, Ming H Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 18, 2000
Adenoviral-mediated suicide gene therapy for ovarian cancer
R D Alvarez, J Gomez-Navarro, M Wang, et al.
Gynecologic Oncology
|
June 28, 2001
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
S D Barker, E Casado, J Gomez-Navarro, et al.
Gynecologic Oncology
|
March 4, 2008
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival
David S Alberts, Christian Marth, Ronald D Alvarez, et al.
Gynecologic Oncology Reports
|
January 22, 2026
Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers
Nikita Bastin, Halle Petrie, Marc Robinson, et al.
Page
of 65